#United States #Florida Cancer Specialists #Fort Myers #AVBCC #Cancer Care Summit

Innovations in Cancer Care: Insights from the AVBCC Summit

The Association for Value-Based Cancer Care (AVBCC) 2026 Educational Summit recently hosted leaders from the Florida Cancer Specialists & Research Institute (FCS) to explore the latest innovations and strategies in cancer treatment. The event serves as a vital platform for healthcare professionals to discuss pressing trends, policy changes, and operational strategies that are redefining cancer care delivery.

Dr. David Wenk, an assistant managing physician at FCS, emphasized the groundbreaking changes shaping oncology. He stated that rapid advancements in scientific research and technology are altering the landscape of cancer treatment. Dr. Wenk expressed that the summit provided a unique opportunity for oncology stakeholders to share their experiences and insights, ultimately paving the way for innovative solutions in cancer care.

Among the prominent speakers at the summit was Dr. Lucio N. Gordan, the president and managing physician of FCS. He highlighted the increasing pressure on healthcare providers and payers to simultaneously improve patient outcomes and manage costs effectively. Dr. Gordan remarked, "Our focus is on how innovative care models enhance quality while reducing inconsistencies in treatment. Our ultimate goal is to ensure that patients receive timely and effective care, especially when it comes to life-saving treatments."

During the summit, Dr. Gordan participated in a high-level strategic session titled "As Leaders Lead, Markets Follow," which focused on evaluating real-world data relating to the oncology ecosystem. This session aimed to identify intersections between innovation and affordability in cancer care.

The discussions also covered the standardization of second opinions, led by Dr. Gordan and other panelists, focusing on how second opinions can improve treatment quality and outcomes. They examined the evolving role of AI in supporting decision-making processes involving expert reviews and how technology can address challenges in patient care.

Kiana Mehring, Senior Vice President of Payer Strategy at FCS, was awarded the prestigious AVBCC's 40 Under 40 Cancer Award and contributed her perspectives during the session regarding innovative initiatives by the Centers for Medicare and Medicaid Services (CMS). She underscored the impact of models like the Oncology Care Model (OCM) and the Enhancing Oncology Model (EOM) on improving cancer care reimbursement. "Our commitment to value-based care is unwavering. By sharing our successful practices, we hope to enhance patient outcomes and satisfaction effectively," said Mehring.

With FCS being a standout performer in the OCM pilot program, the organization was recognized for achieving over $140 million in Medicare savings, showcasing the effectiveness of innovative cancer care models.

For over four decades, Florida Cancer Specialists & Research Institute has been pioneering advancements in oncology. Through exhaustive clinical research initiatives, FCS provides patients access to a variety of clinical trials, reinforcing its position as a leader in private oncology practices across Florida and nationally. With more than 180 active clinical trials each year, FCS is committed to ensuring patients have the opportunity to participate in cutting-edge treatments that may not be otherwise accessible.

By partnering with the Sarah Cannon Research Institute, FCS is at the forefront of clinical advancements, offering patients innovative therapies in their local communities. This collaborative effort underscores FCS’s mission to drive progress in cancer treatment while making groundbreaking therapies accessible closer to home.

The discussions at the AVBCC Summit underscore a forward-looking vision for cancer care at Florida Cancer Specialists & Research Institute. With leaders and healthcare professionals dedicated to enhancing the landscape of oncology, the future promises significant advancements in the quality and accessibility of cancer treatment for patients everywhere.